Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 0 | 0 | 330,531 | 108,463 | 48,661 |
| Gross Profit | N/A | N/A | 330,531 | 108,463 | 48,661 |
| Operating Expenses | 555,342 | 487,341 | 527,230 | 449,207 | 344,412 |
| Operating Income | -555,342 | -487,341 | -196,699 | -340,744 | -295,751 |
| Other Income | 42,904 | 64,636 | 51,505 | 14,774 | 4,595 |
| Pre-tax Income | -512,438 | -422,705 | -145,194 | -325,970 | -291,156 |
| Income Tax | 102 | 68 | 30 | 21 | -575 |
| Net Income Continuous | -512,540 | -422,773 | -145,224 | -325,991 | -290,581 |
| Net Income | $-512,540 | $-422,773 | $-145,224 | $-325,991 | $-290,581 |
| EPS Basic Total Ops | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 |
| EPS Basic Continuous Ops | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 |
| EPS Diluted Total Ops | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 |
| EPS Diluted Continuous Ops | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 |
| EPS Diluted Before Non-Recurring Items | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 |
| EBITDA(a) | $-554,412 | $-514,663 | $-223,925 | $-331,998 | $-278,410 |